MedPath

Lifestyle Changes in Fatty Liver; Additive Effect of Honey Intake

Not Applicable
Recruiting
Conditions
Fatty Liver, Nonalcoholic
Interventions
Behavioral: honey intake and lifestyle changes
Behavioral: lifestyle changes
Registration Number
NCT06596109
Lead Sponsor
Cairo University
Brief Summary

honey is a natural functional food used in control cardiovascular risk factors but its effect on fatty liver is not investigated

Detailed Description

Forty fatty liver (non-alcoholic from) patients with obesity are included to be divided into group 1 who will contain 20 patients who will receive honey intake (orally, as a daily total dose of 2 g/kg, this dose will be divided to three equal subdoses, every dose will be administered before meal), low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks. Group 2 who will contain 20 patients who will receive low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • fatty liver (non alcoholic form)
  • both sexes included
  • obese subjects (class I)
Exclusion Criteria
  • cardiac insult
  • respiratory insult
  • renal insult
  • lower limb insult

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
honey intake and lifestyle changeshoney intake and lifestyle changesTwenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive honey intake (orally, as a daily total dose of 2 g/kg, this dose will be divided to three equal subdoses, every dose will be administered before meal), low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
lifestyle changeslifestyle changesTwenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
Primary Outcome Measures
NameTimeMethod
High density lipoproteinit will be assessed after 12 weeks

it will be measured in serum

Secondary Outcome Measures
NameTimeMethod
triglyceridesit will be assessed after 12 weeks

it will be measured in serum

cholesterolit will be assessed after 12 weeks

it will be measured in serum

low density lipoproteinit will be assessed after 12 weeks

it will be measured in serum

alanine transamianseit will be assessed after 12 weeks

it will be measured in serum

aspartate transamianseit will be assessed after 12 weeks

it will be measured in serum

fasting blood glucoseit will be measured after 12 weeks

it will be measured in serum

body mass indexit will be measured after 12 weeks

it will be measured on empty stomach

waist circumferenceit will be measured after 12 weeks

it will be measured on empty stomach

Trial Locations

Locations (1)

faculty of physical therapy Cairo university

🇪🇬

Dokki, Giza, Egypt

© Copyright 2025. All Rights Reserved by MedPath